Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status

By Kang Myoung  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1607-1613

Springer Publishing Company

Access to resources Recommend Favorite

KRAS status predicts response to cetuximab in mCRC

By  

Inpharma, Vol. 1, Iss. 1641, 2008-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations

By  

Current Cancer Drug Targets, Vol. 18, Iss. 3, 2018-02 ,pp. : 278-286

Bentham Science Publishers

Access to resources Recommend Favorite

EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment In Vivo

By  

Current Cancer Drug Targets, Vol. 17, Iss. 1, 2016-12 ,pp. : 89-97

Bentham Science Publishers

Access to resources Recommend Favorite

Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer

By Park Jinah  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1404-1412

Springer Publishing Company

Access to resources Recommend Favorite